Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout [Yahoo! Finance]
Catalent, Inc. (CTLT)
Last catalent, inc. earnings: 2/3 07:30 am
Check Earnings Report
US:NYSE Investor Relations:
investor.catalent.com
Company Research
Source: Yahoo! Finance
Catalent is a manufacturing partner of Danish company Novo for Wegovy, its popular and highly effective weight-loss drug from the GLP-1 class which some analysts predict could become a $150 billion market by 2030. It also makes Sarepta Therapeutics' gene therapy Elevidys and others. In response to the criticism, CEO Maselli reiterated in a letter to the company's customers that Catalent will continue to operate as an independent contract drugmaker. "I want to be clear: our commitments to you will not change, your products will remain our focus and your proprietary information will be protected." Maselli has been Catalent's CEO for over two years, and during his tenure the company conducted a strategic review as part of a settlement with activist investor Elliott Investment Management, which had been pushing for changes following manufacturing problems and declining revenue. The deal with Novo Holding has secured approval from Brazil's antitrust regulator, but is awaiting clea
Show less
Read more
Impact Snapshot
Event Time:
CTLT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTLT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTLT alerts
High impacting Catalent, Inc. news events
Weekly update
A roundup of the hottest topics
CTLT
News
- Catalent, Inc. (NYSE: CTLT) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- FDA (Food and Drug Administration) Drug Approval Process Training Course: Comprehensive Programme Covering Procedures for Submission of INDs, NDAs, ANDAs and 505(b)(2) (LIVE ONLINE EVENT/ON-DEMAND) [Yahoo! Finance]Yahoo! Finance
- Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery [Yahoo! Finance]Yahoo! Finance
- Matica Biotechnology Appoints Life Sciences Leader Min Park, MBA to Chief Commercial Officer [Yahoo! Finance]Yahoo! Finance
- Pharmaceutical Outsourcing Launches New Clinical Trials Documentary: Transforming Drug Development: Accelerating Clinical Trials through Patient-Centric Innovations and Technological Breakthroughs [Yahoo! Finance]Yahoo! Finance
CTLT
Earnings
- 8/29/24 - Miss
CTLT
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form 4
- 11/14/24 - Form SC
- CTLT's page on the SEC website